UK Markets close in 5 hrs 3 mins

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.1500-0.0800 (-1.89%)
At close: 04:00PM EST
4.1500 0.00 (0.00%)
After hours: 04:00PM EST

Adaptimmune Therapeutics plc

60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom
44 12 3543 0000

Full-time employees462

Key executives

NameTitlePayExercisedYear born
Mr. Adrian G. RawcliffeCEO, Principal Accounting Officer & Director986.26k150.64k1972
Dr. Helen Katrina Tayton-MartinCo-Founder & Chief Bus. Officer703.67kN/A1967
Mr. Gavin Hilary James Wood BA (Hons), ACAChief Financial Officer577.64kN/A1970
Mr. William C. Bertrand Jr.Chief Operating Officer693.45k41.93k1965
Mr. John LungerChief Patient Supply Officer629.8k136.97k1970
Mr. Sébastien DesprezVP of Communications & Investor RelationsN/AN/AN/A
Ms. Margaret HenryHead of PR & Company Sec.N/AN/AN/A
Dr. Rafael G. AmadoPres of R&DN/AN/A1964
Dr. Arundathy Nirmalini Pandite M.B.A., M.D.Sr. VP of Clinical Devel.N/AN/A1959
Trupti TrivediHead of Biometrics and VPN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Corporate governance

Adaptimmune Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.